7 articles
Lanzhou lamb rotavirus vaccine (LLR)
Lanzhou lamb rotavirus vaccine (LLR, 罗特威), a live attenuated oral monovalent G10P[12] lamb-strain vaccine by Lanzhou Institute of Biological Products, licensed in China in 2000, with post-marketing effectiveness of roughly 35–77%.
Oral hexavalent reassortant rotavirus live attenuated vaccine (Vero cell)
Oral hexavalent reassortant rotavirus live attenuated vaccine (Vero cell), brand 武生儿轮宝: Wuhan Institute of Biological Products' oral live vaccine against rotavirus G1, G2, G3, G4, G8, G9 in infants 6–36 weeks; NMPA-approved August 2025, first hexavalent rotavirus vaccine globally.
Oral trivalent reassortant rotavirus live attenuated vaccine (Vero cell), LLR3
LLR3 (Reassortant Rotavirus Vaccine, Live, Oral, Trivalent, Vero Cell) is a Chinese human-lamb reassortant rotavirus vaccine covering G2, G3, G4, licensed April 2023 by Lanzhou Institute of Biological Products, with 56.6% efficacy against any-severity rotavirus gastroenteritis.
Rotarix
Rotarix (RIX4414) is GSK's monovalent oral live attenuated human rotavirus vaccine for infants 6-24 weeks, given as two doses; WHO prequalified, licensed in over 100 countries, efficacy 93% in low-mortality countries.
ROTASIIL
ROTASIIL (Rotasiil), Serum Institute of India's oral live attenuated pentavalent rotavirus vaccine (G1-G4, G9), WHO prequalified 2018; 3-dose infant schedule; 67% efficacy in Niger, 36% in India; heat-stable.
ROTASIIL Liquid
ROTASIIL-Liquid (LBRV-PV) is a ready-to-use oral pentavalent rotavirus vaccine by Serum Institute of India, covering G1–G4 and G9, given as 3 doses from 6 weeks of age, WHO prequalified since 2021.
ROTAVAC 5D
ROTAVAC 5D is Bharat Biotech's liquid, ready-to-use oral rotavirus vaccine (116E strain, G9P[11]), WHO prequalified 18 June 2021, stored at 2-8°C for 24 months, given as 5 drops in a 3-dose infant schedule, non-inferior to frozen ROTAVAC.